Monitoring of minimal residual disease (MRD) in chronic myeloid leukemia: recent advances

C Cumbo, L Anelli, G Specchia… - Cancer management and …, 2020 - Taylor & Francis
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm caused by the BCR-ABL1
fusion gene generation as a consequence of the t (9; 22)(q34; q11) rearrangement. The …

[HTML][HTML] Genomic BCR-ABL1 breakpoint characterization by a multi-strategy approach for “personalized monitoring” of residual disease in chronic myeloid leukemia …

C Cumbo, L Impera, CF Minervini, P Orsini, L Anelli… - Oncotarget, 2018 - ncbi.nlm.nih.gov
For monitoring minimal residual disease (MRD) in chronic myeloid leukemia (CML) the most
recommended method is quantitative RT-PCR (RT-qPCR) for measuring BCR-ABL1 …

Manifold-assisted Reverse Transcription-PCR with Real-Time Detection for Measurement of the BCR-ABL Fusion Transcript in Chronic Myeloid Leukemia Patients

G Barbany, A Hagberg, U Olsson-Stromberg… - Clinical …, 2000 - academic.oup.com
Abstract Background: BCR-ABL fusion mRNA expression in bone marrow or peripheral
blood can be used as a measure of minimal residual disease in patients with chronic …

Rapid quantitative detection of BCR-ABL transcripts in chronic myeloid leukemia patients by real-time reverse transcriptase polymerase-chain reaction using …

P Bolufer, GF Sanz, E Barragán, MA Sanz… - …, 2000 - haematologica.org
BACKGROUND AND OBJECTIVES: The limited value of qualitative reverse transcription
polymerase chain-reaction (RT-PCR) for monitoring chronic myeloid leukemia (CML) …

Real-time quantification of different types of bcr-abl transcript in chronic myeloid leukemia

M Amabile, B Giannini, N Testoni, V Montefusco… - …, 2001 - haematologica.org
BACKGROUND AND OBJECTIVES: The most common translocation in chronic myeloid
leukemia (CML) t (9; 22)(q34; q22) produces the BCR/ABL fusion gene. We set up and …

Novel Multiplex Droplet Digital PCR Assays to Monitor Minimal Residual Disease in Chronic Myeloid Leukemia Patients Showing Atypical BCR-ABL1 Transcripts

J Petiti, M Lo Iacono, M Dragani, L Pironi… - Journal of clinical …, 2020 - mdpi.com
BCR-ABL1 fusion transcript is the minimal residual disease marker in chronic myeloid
leukemia; 2% of patients show unusual breakpoints generating atypical transcripts, not …

Monitoring of minimal residual disease in chronic myeloid leukemia

S Faderl, A Hochhaus… - Hematology/Oncology …, 2004 - hemonc.theclinics.com
Chronic myeloid leukemia (CML) has become a paradigm in cancer medicine for how
advances in understanding of the biology of the disease can be translated into the …

Minimal residual disease detection at RNA and leukemic stem cell (LSC) levels: comparison of RT-qPCR, d-PCR and CD26+ stem cell measurements in chronic …

E Abruzzese, M Bocchia, MM Trawinska, D Raspadori… - Cancers, 2023 - mdpi.com
Simple Summary The monitoring of the minimal residual disease (MRD) in Chronic Myeloid
Leukemia is a key element in the management of affected patients because it reflects the …

A rare e13a3 (b2a3) BCR-ABL1 fusion transcript with normal karyotype in chronic myeloid leukemia: the challenges in diagnosis and monitoring minimal residual …

MH Duan, H Li, H Cai - Leukemia Research, 2017 - Elsevier
Patients with chronic myeloid leukemia (CML) have at (9; 22)(q34; q11. 2) or variant
translocation that results in a BCR-ABL1 fusion gene. For many years, conventional …

[HTML][HTML] Quantitative measurement of BCR/abl transcripts usingreal-time polymerase chain reaction

WI Lee, H Kantarjian, A Glassman, M Talpaz, MS Lee - Annals of oncology, 2002 - Elsevier
Background Quantitative real-time polymerase chain reaction (Q-Rt-PCR) is a new tool in
the detection and quantification of the BCR/abl fusion transcripts in chronic myelogenous …